152 results on '"Jiang, Zhongxing"'
Search Results
2. A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody
3. Early progression is associated with worse survival in patients with Waldenström’s macroglobulinemia
4. Cysteine- and glycine-rich protein 1 predicts prognosis and therapy response in patients with acute myeloid leukemia
5. Clinical implications of myeloid malignancy‑related somatic mutations in aplastic anemia
6. Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies
7. Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study
8. Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2V617F mutation
9. Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing
10. FTO promotes Bortezomib resistance via m6A-dependent destabilization of SOD2 expression in multiple myeloma
11. IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells
12. Genetic mutation signature for relapse prediction in normal karyotype acute myeloid leukemia
13. Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China
14. Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1
15. CCL17 acts as an antitumor chemokine in micromilieu‐driven immune skewing
16. Intestinal microbiota score could predict survival following allogeneic hematopoietic stem cell transplantation
17. Prognostic prediction of novel risk scores (AML-DRG and AML-HCT-CR) in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation
18. Evidence of pyroptosis and ferroptosis extensively involved in autoimmune diseases at the single-cell transcriptome level
19. Clinical characteristics, treatment, and prognosis of 118 cases of myeloid sarcoma
20. Downregulation of SMIM3 inhibits growth of leukemia via PI3K-AKT signaling pathway and correlates with prognosis of adult acute myeloid leukemia with normal karyotype
21. GM-CSF impairs erythropoiesis by disrupting erythroblastic island formation via macrophages
22. Dose tapering to withdrawal stage and long‐term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open‐label extension study
23. Vesicular formation regulated by ERK/MAPK pathway mediates human erythroblast enucleation
24. MiR-150-5p regulate T cell activation in severe aplastic anemia by targeting Bach2
25. Efficacy, safety, and survival findings after long‐term follow‐up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis.
26. A gut microbiota score predicting acute graft-versus-host disease following myeloablative allogeneic hematopoietic stem cell transplantation
27. Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia
28. A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia
29. Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment
30. Intestinal Microbiota Can Predict Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
31. Unbiased Single‐Cell Sequencing of Hematopoietic and Immune Cells from Aplastic Anemia Reveals the Contributors of Hematopoiesis Failure and Dysfunctional Immune Regulation.
32. Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions.
33. Targeting TIGIT for cancer immunotherapy: recent advances and future directions.
34. Differential U2AF1 mutation sites, burden and co-mutation genes can predict prognosis in patients with myelodysplastic syndrome
35. Mutational spectrum and prognosis in NRAS-mutated acute myeloid leukemia
36. Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia
37. Targeted single‐cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis‐resistant state in hematologic malignancies.
38. Analysis of Mean Corpuscular Volume and Red Cell Distribution Width in Patients with Aplastic Anemia.
39. IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy.
40. Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2V617F mutation.
41. S212: A RANDOMIZED DOUBLE‐BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE‐2 OR HIGH RISK MYELOFIBROSIS.
42. Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor‐naïve patients with myelofibrosis: Results of a phase II trial.
43. SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the "don't eat me" signal and activating the "eat me" signal.
44. Active Screening of Intestinal Colonization of Carbapenem-Resistant Enterobacteriaceae for Subsequent Bloodstream Infection in Allogeneic Hematopoietic Stem Cell Transplantation.
45. A ratiometric fluorescent probe for cyanide: Convenient synthesis and the proposed mechanism
46. CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia.
47. Crystal Structure of Human CD47 in Complex with Engineered SIRPα.D1(N80A).
48. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy.
49. Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cells.
50. Research progress on dendritic cell vaccines in cancer immunotherapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.